METYROSINE

Post-LOE

metyrosine

Leadingtac Pharmaceutical

ANDAORALCAPSULE

Approved

Sep 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

METYROSINE (metyrosine) by Leadingtac Pharmaceutical is catecholamine synthesis inhibitors [moa]. Approved for catecholamine synthesis inhibitor [epc]. First approved in 2024.

Drug data last refreshed 20h ago

Mechanism of Action

Catecholamine Synthesis Inhibitors

Indications (1)

Catecholamine Synthesis Inhibitor

Clinical Trials (1)

NCT01127503Phase 2Terminated

Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome

Started Jun 2010

2 enrolled

Velo-cardio-facial SyndromePsychosis

Company

Worked on METYROSINE at Leadingtac Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.